Ketamine for chronic non‐cancer pain: A meta‐analysis and trial sequential analysis of randomized controlled trials

Ketamine for chronic non‐cancer pain: A meta‐analysis and trial sequential analysis of... IntroductionChronic pain management remains a challenge for physicians (Argoff et al., ; Birklein et al., ; Finnerup et al., ), particularly as available treatments are only modestly effective in reducing pain. According to a recent meta‐analysis on pharmacotherapy for neuropathic pain, the number needed to treat (NNT) for commonly prescribed drugs ranged from 3 to 6 for a defined goal of just 30 to 50% reduction in pain intensity (Finnerup et al., ). Antidepressants (tricyclics, serotonin and norepinephrine reuptake inhibitors), anti‐epileptics (gabapentin, pregabalin) and opioid agents are commonly prescribed drugs. Unfortunately, they are frequently associated with side effects that result in reduced dosages and limited efficacy (Finnerup et al., ). As a consequence, discovering new medications and exploring optimal pharmacological associations are still significant fields of research in chronic pain management.Ketamine, an NMDA antagonist and anaesthetic agent, was first synthesized in 1962 and is still in use today (Iacobucci et al., ). It is commonly employed as an antihyperalgesia agent intraoperatively and perioperatively (Aveline et al., ; Angst and Clark, ; Abrishamkar et al., ). Given that chronic pain pathophysiology involves glutamate receptor activation, and particularly NMDA receptors (Nijs et al., ; Niesters and Dahan, ; Niesters et al., ; Colloca et al., ), many articles have been published over http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Pain Wiley

Ketamine for chronic non‐cancer pain: A meta‐analysis and trial sequential analysis of randomized controlled trials

Loading next page...
 
/lp/wiley/ketamine-for-chronic-non-cancer-pain-a-meta-analysis-and-trial-lGRxdmTMAC
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
Copyright © 2018 European Pain Federation ‐ EFIC®
ISSN
1090-3801
eISSN
1532-2149
D.O.I.
10.1002/ejp.1153
Publisher site
See Article on Publisher Site

Abstract

IntroductionChronic pain management remains a challenge for physicians (Argoff et al., ; Birklein et al., ; Finnerup et al., ), particularly as available treatments are only modestly effective in reducing pain. According to a recent meta‐analysis on pharmacotherapy for neuropathic pain, the number needed to treat (NNT) for commonly prescribed drugs ranged from 3 to 6 for a defined goal of just 30 to 50% reduction in pain intensity (Finnerup et al., ). Antidepressants (tricyclics, serotonin and norepinephrine reuptake inhibitors), anti‐epileptics (gabapentin, pregabalin) and opioid agents are commonly prescribed drugs. Unfortunately, they are frequently associated with side effects that result in reduced dosages and limited efficacy (Finnerup et al., ). As a consequence, discovering new medications and exploring optimal pharmacological associations are still significant fields of research in chronic pain management.Ketamine, an NMDA antagonist and anaesthetic agent, was first synthesized in 1962 and is still in use today (Iacobucci et al., ). It is commonly employed as an antihyperalgesia agent intraoperatively and perioperatively (Aveline et al., ; Angst and Clark, ; Abrishamkar et al., ). Given that chronic pain pathophysiology involves glutamate receptor activation, and particularly NMDA receptors (Nijs et al., ; Niesters and Dahan, ; Niesters et al., ; Colloca et al., ), many articles have been published over

Journal

European Journal of PainWiley

Published: Jan 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial